Other languages Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Real-time Estimate Cboe BZX Other stock markets 12:57:17 2024-04-29 EDT			5-day change	1st Jan Change
6.97 ^USD	-3.73%		+2.07%	-6.76%

04-24	Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	CI
03-29	Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pasithea Therapeutics Corp. Announces the First Cohort Has Completed the Initial Dosing in Its Phase 1 Trial Evaluating Pas-004 in Ras, Nf1 and Raf Mutated Cancers	04-24
Pasithea Therapeutics Corp. Reports Earnings Results for the Full Year Ended December 31, 2023	03-29
Pasithea Therapeutics Announces Opening of Enrollment in the U.S. for Its Phase 1 Trial of Pas-004	02-13
Top Premarket Decliners	01-12
Pasithea Therapeutics Announces Invention of Crystalline Form of PAS-004; Establishes Strengthened Intellectual Property (IP) Position	01-08
Pasithea Therapeutics Shares Rise on FDA Clearance to Evaluate PAS-004 in Advanced Cancer Patients	01-02
Pasithea Therapeutics Corp. Announces FDA Acceptance of Ind Application to Evaluate Pas-004 in Advanced Cancer Patients	01-02
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	12-12
Pasithea Therapeutics Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-13
Pasithea Therapeutics Corp. Selects PAS-003 Lead Development Candidate	11-09
Pasithea Therapeutics Corp. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, for $4 million.	23-08-09
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	23-08-09
Pasithea Therapeutics Corp. Publishes Study in Proceedings of the National Academy of Sciences Related to its PAS-003 Drug Discovery Program	23-08-01
Pasithea Therapeutics' Board Authorizes Share Repurchase Program Through $4 Million Tender Offer; Shares Rise	23-07-20
Pasithea Therapeutics Corp. announces an Equity Buyback for 5,714,285 shares, representing 21.86% for $4 million.	23-07-20
Pasithea Therapeutics Corp. authorizes a Buyback Plan.	23-07-19
Lucy Scientific Discovery Inc. cancelled the acquisition of Pasithea Therapeutics Corp..	23-07-19
Lucy Scientific Discovery Reiterates Proposal to Acquire Pasithea Therapeutics	23-06-29
Pasithea Therapeutics Confirms Unsolicited Takeover Proposal From Lucy Scientific Discovery	23-06-06

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages Pasithea Therapeutics Corp.

Equities

KTTA

US70261F2020

Other languages

Filters